Tetralogic Pharmaceuticals Corp (TLOG) 6.28 $TLOG
TetraLogic Pharmaceuticals Announces Publication of Structural Characterization of Birinapant
GlobeNewswire - Wed Apr 09, 6:30AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data published in a forthcoming issue of the Journal of Medicinal Chemistry of the American Chemical Society describes the discovery and unique chemical features of its lead Smac-mimetic birinapant, which is currently being tested in Phase 1 and Phase 2 clinical trials for hematological malignancies and solid tumors.
TetraLogic Agrees to Acquire Shape Pharmaceuticals, Inc.
GlobeNewswire - Mon Apr 07, 3:36PM CDT
-- SHAPE, a novel, tissue-targeted topical HDAC inhibitor, is expected to enter Phase 2 trials for early-stage CTCL
TetraLogic Pharmaceuticals (TLOG) Soars: Stock Up 20.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 8:39AM CDT
TetraLogic Pharmaceuticals Corporation was a big mover last session, as its shares rose almost 21% on the day.
TetraLogic Pharmaceuticals Announces Publication of Preclinical Characterization of Birinapant
GlobeNewswire - Tue Apr 01, 6:03AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data published in the April issue of Molecular Cancer Therapeutics further advances the preclinical characterization of its lead SMAC-Mimetic birinapant, which is currently being tested in Phase 1 and Phase 2 clinical trials for hematological malignancies and solid tumors.
TetraLogic to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Mon Mar 31, 6:30AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that J. Kevin Buchi, President and Chief Executive Officer, will present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8, 2014 at 10:40 a.m. Eastern Time in New York, NY. Mr. Buchi will provide an overview of the Company and its corporate activities.
TetraLogic Pharmaceuticals to Present Data From Its SMAC-Mimetic Program at Upcoming AACR Annual Meeting 2014
GlobeNewswire - Thu Mar 27, 3:12PM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data from its novel SMAC-Mimetic program will be presented during presentations at the American Association for Cancer Research (AACR) Annual Meeting being held April 5-9, 2014 at the San Diego Convention Center in San Diego, California.
J. Kevin Buchi, President and Chief Executive Officer, Awarded the Pennsylvania Bio's Frank Baldino Bioscience CEO of the Year
GlobeNewswire - Thu Mar 13, 8:01AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that J. Kevin Buchi, President and Chief Executive Officer, is the recipient of the 2014 Frank Baldino Jr. CEO of the Year Award awarded by Pennsylvania Bio, the statewide life sciences industry trade association. Mr. Buchi was honored at PA Bio's Annual Dinner and Awards Celebration and Ceremony on March 12, 2014 in Philadelphia.
TetraLogic to Present at the Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Wed Feb 26, 6:30AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that J. Kevin Buchi, President and Chief Executive Officer, will present at the Cowen and Company 34 Annual Health Care Conference on Wednesday, March 5, 2014 at 8:40 a.m. Eastern Time in Boston, MA. Mr. Buchi will provide an overview of the Company and its corporate activities.
Over 25 Companies to Present at Emerald Groundhog Investment Forum: Thursday, February 6th
Business Wire - Tue Feb 04, 3:12PM CST
Pennsylvania's famous groundhog Punxsutawney Phil may have forecast six more weeks of winter, but he's delivering clear skies and a perfect day for the Groundhog Day Investment Forum on Thursday, February 6th. Emerald Asset Management, Inc. will welcome hundreds of investment industry professionals to the Radisson Warwick Hotel in Philadelphia, PA for the 21st annual event. This year's Forum will include sessions focusing on cyber security, the robotics revolution, local and regional banks, fixed income securities and alternatives and ongoing innovations by corporate America generating potential investment opportunities.
Investment Industry to Gather in Philadelphia at 21st Annual Groundhog Investment Forum
Business Wire - Thu Jan 30, 1:00PM CST
Emerald Asset Management, Inc. will welcome hundreds of investment industry professionals to the 21st annual Emerald Groundhog Day Investment Forum, scheduled to be held on Thursday, February 6th at the Radisson Warwick Hotel in Philadelphia, PA. "We say that the 2014 investment year begins in earnest with our annual Forum," said Emerald CEO and Founder Joseph E. Besecker. "Public company senior managers, investment portfolio managers and research analysts come together to review 2013 and provide their initial outlook to 2014 and beyond." This year's Forum will include sessions focusing on cyber security, the robotics revolution, local and regional banks, fixed income securities and alternatives and ongoing innovations by corporate America generating potential investment opportunities.
TetraLogic Announces Licensing and Research Collaboration With Walter and Eliza Hall Institute of Medical Research
GlobeNewswire - Tue Jan 21, 6:30AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that it has entered into a research collaboration with the Walter and Eliza Hall Institute of Medical Research to examine TetraLogic's SMAC-Mimetic birinapant in viral infections. Preclinical studies performed at the WEHI have indicated that SMAC-Mimetics decrease the viral burden in mice with human Hepatitis B Virus (HBV) by inducing apoptosis of virally infected hepatocytes while sparing the non-infected cells.
TetraLogic Announces Exercise of Over-Allotment Option
GlobeNewswire - Tue Dec 31, 3:05PM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that the underwriters for its initial public offering of common stock have exercised their option to purchase an additional 1,072,115 shares of common stock at a public offering price of $7.00 per share, before the underwriting discount. The closing of the option exercise occurred on December 31, 2013, resulting in net proceeds to TetraLogic of approximately $6,970,000 after the underwriting discount and offering costs.
Nasdaq stocks posting largest percentage increases
AP - Mon Dec 30, 4:59PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
TetraLogic Pharmaceuticals Corporation [TLOG] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Wed Dec 18, 9:00AM CST
What:
TetraLogic Announces Closing of Initial Public Offering of Common Stock
GlobeNewswire - Tue Dec 17, 3:05PM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced the closing of its initial public offering of 7,150,000 shares of its common stock at a public offering price of $7.00 per share, before the underwriting discount and offering costs. As a result, aggregate net proceeds to TetraLogic, after the underwriting discount and offering costs, were approximately $43,100,000.
Nextech Invest Portfolio Company TetraLogic Pharmaceuticals Starts Trading on NASDAQ
Thomson Reuters ONE - Fri Dec 13, 3:36AM CST
Nextech Invest AG / Nextech Invest Portfolio Company TetraLogic Pharmaceuticals Starts Trading on NASDAQ . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Not just Hilton: 5 other companies make debut
By The Associated Press - AP - Thu Dec 12, 5:17PM CST
Six companies began trading Thursday, including hotelier Hilton Worldwide Holdings Inc., which raised $2.35 billion, and cafeteria and concession stand operator Aramark Holdings Corp., which raised $725 million. Hilton closed up 7.5 percent while Aramark gained 13.5 percent.
TetraLogic Announces Pricing of Initial Public Offering of Common Stock
GlobeNewswire - Thu Dec 12, 6:30AM CST
TetraLogic Pharmaceuticals Corporation (TetraLogic) today announced pricing of its initial public offering of 7,150,000 shares of its common stock at a public offering price of $7.00 per share, before underwriting discount and offering costs. All of the shares of common stock are being offered by TetraLogic. In addition, TetraLogic has granted the underwriters a 30-day option to purchase up to an additional 1,072,500 shares of common stock at the same price to cover over-allotments, if any. The shares are expected to begin trading on the NASDAQ Global Market on December 12, 2013 under the symbol "TLOG."
Burns Drug Pipeline Review Report, H2 2013 Edition
M2 - Wed Nov 06, 10:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/qh763q/burns_pipeline) has announced the addition of the "Burns - Pipeline Review, H2 2013" report to their offering. 'Burns - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Burns, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Burns. Scope - A snapshot of the global therapeutic scenario for Burns. - A review of the Burns products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Burns pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned - Hanall Pharmaceutical Co., Ltd. - CytoTools AG - Shenzhen Beike Biotechnology Co., Ltd. - ConjuGon, Inc. - Ventria Bioscience - TetraLogic Pharmaceuticals - Destiny Pharma Ltd. - NanoBio Corporation - USV Limited. - Adocia - Fibrocell Sciences, Inc. - Se-cure Pharmaceuticals Ltd. - AlgiPharma AS - Birken GmbH For more information visit http://www.researchandmarkets.com/research/qh...s_pipeline
TetraLogic Pharmaceuticals Announces Publication of Structural Characterization of Birinapant
GlobeNewswire - Wed Apr 09, 6:30AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data published in a forthcoming issue of the Journal of Medicinal Chemistry of the American Chemical Society describes the discovery and unique chemical features of its lead Smac-mimetic birinapant, which is currently being tested in Phase 1 and Phase 2 clinical trials for hematological malignancies and solid tumors.
TetraLogic Agrees to Acquire Shape Pharmaceuticals, Inc.
GlobeNewswire - Mon Apr 07, 3:36PM CDT
-- SHAPE, a novel, tissue-targeted topical HDAC inhibitor, is expected to enter Phase 2 trials for early-stage CTCL
TetraLogic Pharmaceuticals (TLOG) Soars: Stock Up 20.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 8:39AM CDT
TetraLogic Pharmaceuticals Corporation was a big mover last session, as its shares rose almost 21% on the day.
TetraLogic Pharmaceuticals Announces Publication of Preclinical Characterization of Birinapant
GlobeNewswire - Tue Apr 01, 6:03AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data published in the April issue of Molecular Cancer Therapeutics further advances the preclinical characterization of its lead SMAC-Mimetic birinapant, which is currently being tested in Phase 1 and Phase 2 clinical trials for hematological malignancies and solid tumors.
TetraLogic to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Mon Mar 31, 6:30AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that J. Kevin Buchi, President and Chief Executive Officer, will present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8, 2014 at 10:40 a.m. Eastern Time in New York, NY. Mr. Buchi will provide an overview of the Company and its corporate activities.
TetraLogic Pharmaceuticals to Present Data From Its SMAC-Mimetic Program at Upcoming AACR Annual Meeting 2014
GlobeNewswire - Thu Mar 27, 3:12PM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data from its novel SMAC-Mimetic program will be presented during presentations at the American Association for Cancer Research (AACR) Annual Meeting being held April 5-9, 2014 at the San Diego Convention Center in San Diego, California.
J. Kevin Buchi, President and Chief Executive Officer, Awarded the Pennsylvania Bio's Frank Baldino Bioscience CEO of the Year
GlobeNewswire - Thu Mar 13, 8:01AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that J. Kevin Buchi, President and Chief Executive Officer, is the recipient of the 2014 Frank Baldino Jr. CEO of the Year Award awarded by Pennsylvania Bio, the statewide life sciences industry trade association. Mr. Buchi was honored at PA Bio's Annual Dinner and Awards Celebration and Ceremony on March 12, 2014 in Philadelphia.
TetraLogic to Present at the Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Wed Feb 26, 6:30AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that J. Kevin Buchi, President and Chief Executive Officer, will present at the Cowen and Company 34 Annual Health Care Conference on Wednesday, March 5, 2014 at 8:40 a.m. Eastern Time in Boston, MA. Mr. Buchi will provide an overview of the Company and its corporate activities.
Over 25 Companies to Present at Emerald Groundhog Investment Forum: Thursday, February 6th
Business Wire - Tue Feb 04, 3:12PM CST
Pennsylvania's famous groundhog Punxsutawney Phil may have forecast six more weeks of winter, but he's delivering clear skies and a perfect day for the Groundhog Day Investment Forum on Thursday, February 6th. Emerald Asset Management, Inc. will welcome hundreds of investment industry professionals to the Radisson Warwick Hotel in Philadelphia, PA for the 21st annual event. This year's Forum will include sessions focusing on cyber security, the robotics revolution, local and regional banks, fixed income securities and alternatives and ongoing innovations by corporate America generating potential investment opportunities.
Investment Industry to Gather in Philadelphia at 21st Annual Groundhog Investment Forum
Business Wire - Thu Jan 30, 1:00PM CST
Emerald Asset Management, Inc. will welcome hundreds of investment industry professionals to the 21st annual Emerald Groundhog Day Investment Forum, scheduled to be held on Thursday, February 6th at the Radisson Warwick Hotel in Philadelphia, PA. "We say that the 2014 investment year begins in earnest with our annual Forum," said Emerald CEO and Founder Joseph E. Besecker. "Public company senior managers, investment portfolio managers and research analysts come together to review 2013 and provide their initial outlook to 2014 and beyond." This year's Forum will include sessions focusing on cyber security, the robotics revolution, local and regional banks, fixed income securities and alternatives and ongoing innovations by corporate America generating potential investment opportunities.
TetraLogic Announces Licensing and Research Collaboration With Walter and Eliza Hall Institute of Medical Research
GlobeNewswire - Tue Jan 21, 6:30AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that it has entered into a research collaboration with the Walter and Eliza Hall Institute of Medical Research to examine TetraLogic's SMAC-Mimetic birinapant in viral infections. Preclinical studies performed at the WEHI have indicated that SMAC-Mimetics decrease the viral burden in mice with human Hepatitis B Virus (HBV) by inducing apoptosis of virally infected hepatocytes while sparing the non-infected cells.
TetraLogic Announces Exercise of Over-Allotment Option
GlobeNewswire - Tue Dec 31, 3:05PM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that the underwriters for its initial public offering of common stock have exercised their option to purchase an additional 1,072,115 shares of common stock at a public offering price of $7.00 per share, before the underwriting discount. The closing of the option exercise occurred on December 31, 2013, resulting in net proceeds to TetraLogic of approximately $6,970,000 after the underwriting discount and offering costs.
Nasdaq stocks posting largest percentage increases
AP - Mon Dec 30, 4:59PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
TetraLogic Pharmaceuticals Corporation [TLOG] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Wed Dec 18, 9:00AM CST
What:
TetraLogic Announces Closing of Initial Public Offering of Common Stock
GlobeNewswire - Tue Dec 17, 3:05PM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced the closing of its initial public offering of 7,150,000 shares of its common stock at a public offering price of $7.00 per share, before the underwriting discount and offering costs. As a result, aggregate net proceeds to TetraLogic, after the underwriting discount and offering costs, were approximately $43,100,000.
Nextech Invest Portfolio Company TetraLogic Pharmaceuticals Starts Trading on NASDAQ
Thomson Reuters ONE - Fri Dec 13, 3:36AM CST
Nextech Invest AG / Nextech Invest Portfolio Company TetraLogic Pharmaceuticals Starts Trading on NASDAQ . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Not just Hilton: 5 other companies make debut
By The Associated Press - AP - Thu Dec 12, 5:17PM CST
Six companies began trading Thursday, including hotelier Hilton Worldwide Holdings Inc., which raised $2.35 billion, and cafeteria and concession stand operator Aramark Holdings Corp., which raised $725 million. Hilton closed up 7.5 percent while Aramark gained 13.5 percent.
TetraLogic Announces Pricing of Initial Public Offering of Common Stock
GlobeNewswire - Thu Dec 12, 6:30AM CST
TetraLogic Pharmaceuticals Corporation (TetraLogic) today announced pricing of its initial public offering of 7,150,000 shares of its common stock at a public offering price of $7.00 per share, before underwriting discount and offering costs. All of the shares of common stock are being offered by TetraLogic. In addition, TetraLogic has granted the underwriters a 30-day option to purchase up to an additional 1,072,500 shares of common stock at the same price to cover over-allotments, if any. The shares are expected to begin trading on the NASDAQ Global Market on December 12, 2013 under the symbol "TLOG."
Burns Drug Pipeline Review Report, H2 2013 Edition
M2 - Wed Nov 06, 10:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/qh763q/burns_pipeline) has announced the addition of the "Burns - Pipeline Review, H2 2013" report to their offering. 'Burns - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Burns, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Burns. Scope - A snapshot of the global therapeutic scenario for Burns. - A review of the Burns products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Burns pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned - Hanall Pharmaceutical Co., Ltd. - CytoTools AG - Shenzhen Beike Biotechnology Co., Ltd. - ConjuGon, Inc. - Ventria Bioscience - TetraLogic Pharmaceuticals - Destiny Pharma Ltd. - NanoBio Corporation - USV Limited. - Adocia - Fibrocell Sciences, Inc. - Se-cure Pharmaceuticals Ltd. - AlgiPharma AS - Birken GmbH For more information visit http://www.researchandmarkets.com/research/qh...s_pipeline
